Biotech · Private company · Houston, TX, US
March Biosciences Inc
Track this companyFree. Adds March Biosciences Inc to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- Genetic: MB-105Phase 2 · Lymphoma, T-CellClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- MB-105 in Patients With CD5 Positive T-cell LymphomaPHASE2 · RECRUITING · started Feb 15, 2025ClinicalTrials.gov NCT06534060 · fetched Nov 12, 2026
NIH awards5
- Overcoming Immune Evasion in Hepatocellular Carcinoma with Engineered T-Cell TherapyFiscal year 2026 · $399KNIH RePORTER 1R44CA314963-01 · fetched Nov 12, 2026
- A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphomaFiscal year 2026 · $1.1MNIH RePORTER 5R44CA302357-02 · fetched Nov 12, 2026
- A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphomaFiscal year 2025 · $1.1MNIH RePORTER 1R44CA302357-01 · fetched Nov 12, 2026
- Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignanciesFiscal year 2025 · $986.1KNIH RePORTER 5R44CA295245-02 · fetched Nov 12, 2026
- Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignanciesFiscal year 2024 · $1MNIH RePORTER 1R44CA295245-01 · fetched Nov 12, 2026